Distinguished in Mitochondrial Complex V Deficiency

Kei Murayama

Tokyo, JP 
Distinguished in Mitochondrial Complex V Deficiency
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Kei Murayama practices in Tokyo, Japan. Murayama is rated as a Distinguished expert by MediFind in the treatment of Mitochondrial Complex V Deficiency. Their top areas of expertise are Leigh Syndrome, Ornithine Transcarbamylase Deficiency, Urea Cycle Disorders (UCD), Liver Transplant, and Bone Marrow Aspiration.

Their clinical research consists of co-authoring 208 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Mitochondrial Complex V Deficiency.

Locations

Tokyo, Japan
Other Locations
Chiba, Japan
Hongo, 1138421, Japan
Nishi, 9690223, Japan
Heta, 2660007, Japan
Chuo, Japan
Midori, Japan
Sendai, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Other, Drug
Study Drug: Vatiquinone
Study Phase: Phase 2/Phase 3

208 Total Publications

Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study.
Efficacy and Safety of 5-Aminolevulinic Acid Hydrochloride Combined with Sodium Ferrous Citrate in Pediatric Patients with Leigh Syndrome and Central Nervous System Disorders: An Initial Exploratory Trial with a Double-Blind Placebo-Controlled Period, Followed by an Open-Label Period and a Subsequent Long-Term Administration Study.
Journal: Life (Basel, Switzerland)
Published: June 18, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Murayama's expertise for a condition
ConditionClose
    View All 8 Distinguished Conditions
    View All 15 Advanced Conditions
    View All 96 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile